50
Participants
Start Date
January 31, 2005
Primary Completion Date
March 31, 2011
Study Completion Date
March 31, 2011
aldesleukin
Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.
natural killer cells
Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10\^7 cells/kg.
cyclophosphamide
Administered intravenously (IV) 50 mg/kg on Day -15
fludarabine phosphate
Administered intravenously (IV) 40 mg/m\^2 on Days -18 through -14
allogeneic hematopoietic stem cell transplantation
On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.
total body irradiation
Administered on Day -13, 200 cGy two times.
Thymoglobulin
intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)
Cyclosporin A
1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.
cyclophosphamide
Administered intravenously (IV) 50 mg/kg on Days -16 and -15
fludarabine phosphate
Administered intravenously (IV) 35 mg/m\^2 on Days -18 through -14
Masonic Cancer Center, University of Minnesota, Minneapolis
Masonic Cancer Center, University of Minnesota
OTHER